ArticleJTO clinical and research reports2022

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial.

Makoto Hibino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.